Evaluation on the compliance with secondary prevention and influence factors of ischemic stroke in Hainan province, China.
Survivors of ischemic stroke are still at a significant risk for recurrence. Numerous effective strategies for the secondary prevention of ischemic stroke have now been established; however, these guidelines are not widely known. In this retrospective, a multicenter study was conducted from January 2011 to February 2012 in 10 general hospitals, which included 1300 elderly patients who had previously been diagnosed with ischemic stroke and re-admitted to hospitals. Logistic regression models were fitted to determine the relationship between compliance with secondary prevention therapy and each variable of interest. The treatment rates of antihypertensive, antiplatelet and lipid-lowering therapy were only 56.3%, 48.9% and 19.6%, respectively. Multivariate analysis presented that cardiovascular risk factors would motivate patients with hypertension and hyperlipidemia to receive corresponding treatments. However, it is worth noting that they did not influence the use of antiplatelet therapy. In addition, high education, health education and insurance promote the use of secondary prevention in patients. In conclusion, the importance of antiplatelet therapy should not be ignored any more. Besides, health education will raise patients' attention to ischemic stroke.
Qingjie
Q
Su
Kunxiong
K
Yuan
Faqing
F
Long
Zhongqin
Z
Wan
Chaoyun
C
Li
Yi
Y
Cai
Chaosheng
C
Zeng
Yingman
Y
Wu
Hairong
H
Wu
Shu
S
Liu
Pengxiang
P
Li
Jingxia
J
Zhou
Cong
C
Chen
Desheng
D
Wang
Limin
L
Yan
Yuhui
Y
Zhang
Mingming
M
Dai
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002681:China / Q000453:epidemiology; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D020380:Needs Assessment; D010359:Patient Readmission / Q000706:statistics & numerical data; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors